These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

207 related items for PubMed ID: 7812676

  • 21. Inhibitory effects of the novel platelet activating factor receptor antagonist, 1-ethyl-2-[N-(2-methoxy)benzoyl-N-[(2R)-2-methoxy-3-(4- octadecylcarbamoyloxy) piperidinocarbonyloxypropyloxy]carbonyl] aminomethyl-pyridinium chloride, in several experimentally induced shock models.
    Nagaoka J, Harada K, Kimura A, Kobayashi S, Murakami M, Yoshimura T, Yamada K, Asano O, Katayama K, Yamatsu I.
    Arzneimittelforschung; 1991 Jul; 41(7):719-24. PubMed ID: 1663352
    [Abstract] [Full Text] [Related]

  • 22. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
    Yamada T, Saito M, Mase T, Hara H, Nagaoka H, Murase K, Tomioka K.
    Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
    [Abstract] [Full Text] [Related]

  • 23. Pharmacological characterization of a receptor for platelet-activating factor on guinea pig peritoneal macrophages using [3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation.
    Ring PC, Seldon PM, Barnes PJ, Giembycz MA.
    Mol Pharmacol; 1993 Feb; 43(2):302-12. PubMed ID: 8381515
    [Abstract] [Full Text] [Related]

  • 24. 1,4-Dihydropyridines as antagonists of platelet activating factor. 1. Synthesis and structure-activity relationships of 2-(4-heterocyclyl)phenyl derivatives.
    Cooper K, Fray MJ, Parry MJ, Richardson K, Steele J.
    J Med Chem; 1992 Aug 21; 35(17):3115-29. PubMed ID: 1507200
    [Abstract] [Full Text] [Related]

  • 25. CV-6209, a highly potent antagonist of platelet activating factor in vitro and in vivo.
    Terashita Z, Imura Y, Takatani M, Tsushima S, Nishikawa K.
    J Pharmacol Exp Ther; 1987 Jul 21; 242(1):263-8. PubMed ID: 3612533
    [Abstract] [Full Text] [Related]

  • 26. Pharmacological actions of Y-24180, a new specific antagonist of platelet activating factor (PAF): II. Interactions with PAF and benzodiazepine receptors.
    Takehara S, Mikashima H, Muramoto Y, Terasawa M, Setoguchi M, Tahara T.
    Prostaglandins; 1990 Dec 21; 40(6):571-83. PubMed ID: 1965554
    [Abstract] [Full Text] [Related]

  • 27. Effects of a new platelet-activating factor antagonist, UR-12670, on several endotoxic shock markers in rats.
    Balsa D, Merlos M, Giral M, Ferrando R, Garcia-Rafanell J, Forn J.
    Drugs Exp Clin Res; 1997 Dec 21; 23(5-6):191-9. PubMed ID: 9515229
    [Abstract] [Full Text] [Related]

  • 28. 4-Alkyl-1,4-dihydropyridines derivatives as specific PAF-acether antagonists.
    Sunkel CE, de Casa-Juana MF, Santos L, Gómez MM, Villarroya M, González-Morales MA, Priego JG, Ortega MP.
    J Med Chem; 1990 Dec 21; 33(12):3205-10. PubMed ID: 2175357
    [Abstract] [Full Text] [Related]

  • 29. Biological effect of orally active platelet-activating factor receptor antagonist SM-10661.
    Komuro Y, Imanishi N, Uchida M, Morooka S.
    Mol Pharmacol; 1990 Sep 21; 38(3):378-84. PubMed ID: 2402227
    [Abstract] [Full Text] [Related]

  • 30. Biological effects of the orally active platelet activating factor receptor antagonist SDZ 64-412.
    Handley DA, Van Valen RG, Melden MK, Houlihan WJ, Saunders RN.
    J Pharmacol Exp Ther; 1988 Nov 21; 247(2):617-23. PubMed ID: 3183958
    [Abstract] [Full Text] [Related]

  • 31. Antiaggregant and antivasospastic properties of the new thromboxane A2 receptor antagonist sodium 4-[[1-[[[(4-chlorophenyl)sulfonyl]amino]methyl]cyclopentyl] methyl]benzeneacetate.
    Lardy C, Rousselot C, Chavernac G, Depin JC, Guerrier D.
    Arzneimittelforschung; 1994 Nov 21; 44(11):1196-202. PubMed ID: 7848331
    [Abstract] [Full Text] [Related]

  • 32. Inhibitory effect of new PAF antagonists on PAF-induced rabbit platelet aggregation in vitro and ex vivo.
    Yue TL, Rabinovici R, Farhat M, Feuerstein G.
    J Lipid Mediat; 1991 Nov 21; 3(1):13-26. PubMed ID: 1768837
    [Abstract] [Full Text] [Related]

  • 33. Antiallergic effect of epinastine (WAL 801 CL) on immediate hypersensitivity reactions: (II). Antagonistic effect of epinastine on chemical mediators, mainly antihistaminic and anti-PAF effects.
    Kamei C, Mio M, Kitazumi K, Tsujimoto S, Yoshida T, Adachi Y, Tasaka K.
    Immunopharmacol Immunotoxicol; 1992 Nov 21; 14(1-2):207-18. PubMed ID: 1350791
    [Abstract] [Full Text] [Related]

  • 34. Pharmacological activities of a novel thienodiazepine derivative as a platelet-activating factor antagonist. Effects on microvascular permeability, hypotension and nephrosis.
    Sakuma Y, Shirato M, Nagaoka J, Obaishi H, Tsunoda H, Katayama S, Ono H, Katayama K.
    Arzneimittelforschung; 1991 Dec 21; 41(12):1255-9. PubMed ID: 1815526
    [Abstract] [Full Text] [Related]

  • 35. Protective effect of SR 27417, a novel PAF antagonist, on PAF- or endotoxin-induced hypotension in the rat and the guinea-pig.
    Bernat A, Herbert JM, Salel V, Lespy L, Maffrand JP.
    J Lipid Mediat; 1992 Feb 21; 5(1):41-8. PubMed ID: 1391738
    [Abstract] [Full Text] [Related]

  • 36. Role of platelet-activating factor (PAF) in platelet accumulation in rabbit skin: effect of the novel long-acting PAF antagonist, UK-74,505.
    Pons F, Rossi AG, Norman KE, Williams TJ, Nourshargh S.
    Br J Pharmacol; 1993 May 21; 109(1):234-42. PubMed ID: 8495241
    [Abstract] [Full Text] [Related]

  • 37. Effect of Y-24180, a long-acting antagonist to platelet-activating factor (PAF), on PAF-induced reactions: a relationship between the partial structure of the compound and its duration of the action.
    Kagoshima M, Tomomatsu N, Iwahisa Y, Yamaguchi S, Kawakami Y, Terasawa M.
    Pharmacology; 1997 May 21; 54(5):261-70. PubMed ID: 9380772
    [Abstract] [Full Text] [Related]

  • 38. Pharmacological actions of PCA 4248, a new platelet-activating factor receptor antagonist: in vivo studies.
    Fernández-Gallardo S, Ortega MP, Priego JG, de Casa-Juana MF, Sunkel C, Sánchez Crespo M.
    J Pharmacol Exp Ther; 1990 Oct 21; 255(1):34-9. PubMed ID: 2170626
    [Abstract] [Full Text] [Related]

  • 39. Design, synthesis, and structure-activity relationship studies of novel 1-[(1-acyl-4-piperidyl)methyl]-1H-2- methylimidazo[4,5-c]pyridine derivatives as potent, orally active platelet-activating factor antagonists.
    Carceller E, Merlos M, Giral M, Balsa D, García-Rafanell J, Forn J.
    J Med Chem; 1996 Jan 19; 39(2):487-93. PubMed ID: 8558517
    [Abstract] [Full Text] [Related]

  • 40. Novel antagonists of platelet-activating factor. 2. Synthesis and structure-activity relationships of potent and long-acting heterofused [1,5]benzodiazepine and [1,4]diazepine derivatives of 2-methyl-1-phenylimidazo[4,5-c]pyridine.
    Fray MJ, Bull DJ, Cooper K, Parry MJ, Stefaniak MH.
    J Med Chem; 1995 Sep 01; 38(18):3524-35. PubMed ID: 7658439
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.